Drug Trial Radar · NCT01826916
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
Last checked: Nov 20, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Nov 1, 2003
Primary completion
Dec 1, 2005
Study completion Jan 1, 2006
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EDEMA2 is an open-label, Phase 2 dose-ranging study designed to assess the safety and efficacy of repeated dosing of DX-88 (recombinant plasma kallikrein inhibitor) in Patients with Hereditary Angioedema.
Conditions
- Hereditary Angioedema (HAE)
Interventions
DX-88 (ecallantide)Drug
solution for injection 10 mg/mL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of attacks treated with successful outcomeTime frame: 24 hours
- Proportion of attacks with a partial responseTime frame: 24 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.